Drug Profile
Briobacept
Alternative Names: BAFF-R protein therapeutic - Biogen Idec/Genentech; BLyS neutralizing molecule; BR3 Fc - Biogen Idec/GenentechLatest Information Update: 31 May 2010
Price :
$50
*
At a glance
- Originator Biogen Idec; Genentech
- Class Antirheumatics; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; B cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia; Rheumatoid arthritis; Sjogren's syndrome
Most Recent Events
- 14 Jun 2008 Pharmacokinetics, pharmacodynamics and adverse events data from a trial in rheumatoid arthritis presented at the Annual European Congress of Rheumatology (EULAR-2008)
- 29 Nov 2006 Data presented at the 70th Annual Scientific Meeting of the American College of Rheumatology(ACR-2006) added to the adverse events, pharmacokinetics, Rheumatic Disease pharmacodynamics and immunogenicity sections
- 06 Jul 2006 Phase-II clinical trials in Sjogren's syndrome in USA (unspecified route)